Clinical trials: Bacterial Overgrowth
Small Intestinal Bacterial Overgrowth, SIBO
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT06317441
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Nimble Science Ltd.
Bacterial Infections
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.
- Trial name
- NCT01788449
- Volunteers
- 335 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bacterial Overgrowth
Clinical Evaluation of the Residual Antimicrobial Activity
The purpose of this study is to evaluate the residual antimicrobial efficacy of one test product as defined by the difference between the number of a challenge bacterial species recovered following exposure to the test product…
- Trial name
- NCT04495920
- Testing
- CGB-S-100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CAGE Bio Inc.
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Urine Metabolites in the Diagnosis of Disease
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.
- Conditions
- Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
- Trial name
- NCT06710067
- Where
- 4 sites in United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Luventix, Inc.
Infectious Disease
the Clinical Trial of Teicoplanin for Injection
1. Primary study endpoint Security Effectiveness 2. Secondary study endpoint Extensive use of population characteristics Clinical drug characteristics appropriate crowd characteristics Adverse reactions susceptible population…
- Trial name
- NCT03020901
- Testing
- Teicoplanin for Injection
- Volunteers
- 100,000 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.
- Trial name
- NCT04316806
- Testing
- Probiotic, Rifaximin
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- AB Biotics, SA
Resistance Bacterial
T2Resistance - Detection of Resistance Related Genes
The purpose of this study is to evaluate the safety and effectiveness of the T2Resistance Panel by validating clinical performance in three study arms: 1.
- Trial name
- NCT05231187
- Testing
- T2Resistance Panel
- Where
- 10 sites in United States
- Volunteers
- 1,566 people
- Sponsor
- T2 Biosystems
Infection
Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics
Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.
- Trial name
- NCT01311349
- Volunteers
- 1,575 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related…
- Trial name
- NCT04980872
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia
Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas
Demonstrate efficacy of telithromycin over single-agent oral antibiotics usually prescribed by local guidelines ("usual care") for treating adult outpatients with mild to moderate community-acquired pneumonia (CAP) in high…
- Trial name
- NCT00538018
- Testing
- Telithromycin
- Volunteers
- 978 people
- Sponsor
- Sanofi
Small Intestinal Bacterial Overgrowth
Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
The purpose of this study is to determine if the gas-sensing capsule can be used to identify increased numbers and a change of the composition of microbiota or microorganisms in the gut to assess small intestinal dysbiosis
- Trial name
- NCT04910815
- Testing
- Atmo Gas Capsule, Glucose Breath Test, Fructoolifosaccharides (FOS) Breath Test
- Where
- 2 sites in Australia, India
- Volunteers
- 110 people
- Sponsor
- Atmo Biosciences Pty Ltd
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi
Small Intestinal Bacterial Overgrowth
Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth
Study Synopsis This pilot study will determine the efficacy of a novel supplement protocol and low FODMAP diet for the treatment of small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT03420976
- Testing
- Novel Supplement Based Therapy
- Where
- United States
- Sponsor
- Atrium Innovations
Diagnosis, Gonorrhea
Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections
This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples. The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation…
- Conditions
- Diagnosis, Gonorrhea, Resistance Bacterial
- Trial name
- STING (NCT06352554)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SpeeDx Pty Ltd
Complicated Intra-Abdominal Infection
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial…
- Trial name
- NCT00929643
- Testing
- no intervention
- Where
- 13 sites in Greece
- Volunteers
- 203 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Small Intestinal Bacterial Overgrowth (SIBO)
Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)
The purpose of this study is to assess how an oral botanical blend alters the gut microbiome and the skin biophysical properties in people with SIBO.
- Trial name
- NCT04867512
- Testing
- Liquid Tincture, GI Detox, Olivirex
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Small Intestinal Bacterial Overgrowth
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
- Trial name
- NCT06298409
- Testing
- CapScan collection capsule
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Envivo Bio Inc
Drug Resistance, Bacterial, Antimicrobial Drug Resistance
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
The aim of the study is to assess the safety and efficacy of new protocol fecal microbiota transplantation (FMT) in the eradication of antibiotic resistant bacteria, including those featuring of resistance to new generation…
- Trial name
- STOP-ARB2 (NCT06156956)
- Testing
- Fecal Microbiota Transplantation
- Where
- 5 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Human Biome S.A.